AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial
By Christian Moess Laursen
AstraZeneca said its Imfinzi cancer treatment produced positive results in bladder cancer tests, although it didn't meet the primary endpoint in a lung cancer trial.
The British-Swedish pharma giant said Tuesday that Imfinzi in combination with chemotherapy showed significant improvement in the time patients remain free of complications after the end of treatment, as well as in the overall survival rate, for muscle-invasive bladder cancer.
The Phase 3 trial results support AstraZeneca's strategy to move immunotherapy--using the immune system to fight the disease--to the early stages of cancer treatment, the company said.
Bladder cancer is the ninth most common cancer in the world, with more than 614,000 patients diagnosed each year, AstraZeneca said.
In a separate release, AstraZeneca said Imfinzi didn't meet the primary endpoint of disease-free survival in non-small cell lung cancer trial results.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
June 25, 2024 02:52 ET (06:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations